|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Glimelius B, Ekström K, Hoffman K, et al:
Randomized comparison between chemotherapy plus best supportive
care with best supportive care in advanced gastric cancer. Ann
Oncol. 8:163–168. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Murad AM, Santiago FF, Petroianu A, Rocha
PR, Rodrigues MA and Rausch M: Modified therapy with
5-fluorouracil, doxorubicin, and methotrexate in advanced gastric
cancer. Cancer. 72:37–41. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pyrhönen S, Kuitunen T, Nyandoto P and
Kouri M: Randomised comparison of fluorouracil, epidoxorubicin and
methotrexate (FEMTX) plus supportive care with supportive care
alone in patients with non-resectable gastric cancer. Br J Cancer.
71:587–591. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wagner AD, Grothe W, Haerting J, Kleber G,
Grothey A and Fleig WE: Chemotherapy in advanced gastric cancer: A
systematic review and meta-analysis based on aggregate data. J Clin
Oncol. 24:2903–2909. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Van Cutsem E, Moiseyenko VM, Tjulandin S,
et al V325 Study Group: Phase III study of docetaxel and cisplatin
plus fluorouracil compared with cisplatin and fluorouracil as
first-line therapy for advanced gastric cancer: A report of the
V325 Study Group. J Clin Oncol. 24:4991–4997. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Roth AD, Fazio N, Stupp R, et al Swiss
Group for Clinical Cancer Research: Docetaxel, cisplatin, and
fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin,
and fluorouracil as systemic treatment for advanced gastric
carcinoma: A randomized phase II trial of the Swiss Group for
Clinical Cancer Research. J Clin Oncol. 25:3217–3223. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bernards N, Creemers GJ, Nieuwenhuijzen
GA, Bosscha K, Pruijt JF and Lemmens VE: No improvement in median
survival for patients with metastatic gastric cancer despite
increased use of chemotherapy. Ann Oncol. 24:3056–3060. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lordick F, Lorenzen S, Stollfuss J, et al:
Phase II study of weekly oxaliplatin plus infusional fluorouracil
and folinic acid (FUFOX regimen) as first-line treatment in
metastatic gastric cancer. Br J Cancer. 93:190–194. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Al-Batran SE, Atmaca A, Hegewisch-Becker
S, et al: Phase II trial of biweekly infusional fluorouracil,
folinic acid, and oxaliplatin in patients with advanced gastric
cancer. J Clin Oncol. 22:658–663. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yeh YS, Tsai HL, Ma CJ, Wu DC, Lu CY, Wu
IC, Hou MF and Wang JY: A retrospective study of the safety and
efficacy of a first-line treatment with modified FOLFOX-4 in
unresectable advanced or recurrent gastric cancer patients.
Chemotherapy. 58:411–418. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
De Vita F, Orditura M, Matano E, et al: A
phase II study of biweekly oxaliplatin plus infusional
5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment
of advanced gastric cancer patients. Br J Cancer. 92:1644–1649.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chao Y, Yeh KH, Chang CJ, Chen LT, Chao
TY, Wu MF, Chang CS, Chang JY, Chung CY, Kao WY, et al: Phase II
study of weekly oxaliplatin and 24-h infusion of high-dose
5-fluorouracil and folinic acid in the treatment of advanced
gastric cancer. Br J Cancer. 91:453–458. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Eisenhauer EA, Therasse P, Bogaerts J, et
al: New response evaluation criteria in solid tumours: Revised
RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cirillo M, Venturini M, Ciccarelli L,
Coati F, Bortolami O and Verlato G: Clinician versus nurse symptom
reporting using the National Cancer Institute-Common Terminology
Criteria for Adverse Events during chemotherapy: Results of a
comparison based on patient's self-reported questionnaire. Ann
Oncol. 20:1929–1935. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ajani JA, Fodor MB, Tjulandin SA,
Moiseyenko VM, Chao Y, Cabral Filho S, Majlis A, Assadourian S and
Van Cutsem E: Phase II multi-institutional randomized trial of
docetaxel plus cisplatin with or without fluorouracil in patients
with untreated, advanced gastric, or gastroesophageal
adenocarcinoma. J Clin Oncol. 23:5660–5667. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cunningham D, Starling N, Rao S, Iveson T,
Nicolson M, Coxon F, Middleton G, Daniel F, Oates J and Norman
ARUpper Gastrointestinal Clinical Studies Group of the National
Cancer Research Institute of the United Kingdom: Capecitabine and
oxaliplatin for advanced esophagogastric cancer. N Engl J Med.
358:36–46. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Koizumi W, Narahara H, Hara T, et al: S-1
plus cisplatin versus S-1 alone for first-line treatment of
advanced gastric cancer (SPIRITS trial): A phase III trial. Lancet
Oncol. 9:215–221. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Moehler M, Kanzler S, Geissler M, Raedle
J, Ebert MP, Daum S, Flieger D, Seufferlein T, Galle PR and Hoehler
TArbeitsgemeinschaft Internistische Onkologie Germany: A randomized
multicenter phase II study comparing capecitabine with irinotecan
or cisplatin in metastatic adenocarcinoma of the stomach or
esophagogastric junction. Ann Oncol. 21:71–77. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Luo HY, Xu RH, Zhang L, et al: A pilot
study of oxaliplatin, fluorouracil and folinic acid (FOLFOX-6) as
first-line chemotherapy in advanced or recurrent gastric cancer.
Chemotherapy. 54:228–235. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lee HH, Hur H, Kim SH, Park AR, Kim W and
Jeon HM: Outcomes of modified FOLFOX-6 as first line treatment in
patients with advanced gastric cancer in a single institution;
retrospective analysis. Cancer Res Treat. 42:18–23. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Louvet C, André T, Tigaud JM, et al: Phase
II study of oxaliplatin, fluorouracil, and folinic acid in locally
advanced or metastatic gastric cancer patients. J Clin Oncol.
20:4543–4548. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cavanna L, Artioli F, Codignola C, et al:
Oxaliplatin in combination with 5-fluorouracil (5-FU) and
leucovorin (LV) in patients with metastatic gastric cancer (MGC).
Am J Clin Oncol. 29:371–375. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hwang WS, Chao TY, Lin SF, Chung CY, Chiu
CF, Chang YF, Chen PM and Chiou TJ: Phase II study of oxaliplatin
in combination with continuous infusion of
5-fluorouracil/leucovorin as first-line chemotherapy in patients
with advanced gastric cancer. Anticancer Drugs. 19:283–288. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Vogel CL, Wojtukiewicz MZ, Carroll RR,
Tjulandin SA, Barajas-Figueroa LJ, Wiens BL, Neumann TA and
Schwartzberg LS: First and subsequent cycle use of pegfilgrastim
prevents febrile neutropenia in patients with breast cancer: A
multicenter, double-blind, placebo-controlled phase III study. J
Clin Oncol. 23:1178–1184. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Martín M, Lluch A, Seguí MA, et al:
Toxicity and health-related quality of life in breast cancer
patients receiving adjuvant docetaxel, doxorubicin,
cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and
cyclophosphamide (FAC): Impact of adding primary prophylactic
granulocyte-colony stimulating factor to the TAC regimen. Ann
Oncol. 17:1205–1212. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Aapro MS, Cameron DA, Pettengell R, et al:
European Organisation for Research and Treatment of Cancer (EORTC)
Granulocyte Colony-Stimulating Factor (G-CSF) Guidelines Working
Party: EORTC guidelines for the use of granulocyte
colony-stimulating factor to reduce the incidence of
chemotherapy-induced febrile neutropenia in adult patients with
lymphomas and solid tumours. Eur J Cancer. 42:2433–2453. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
National Comprehensive Cancer Network.
Practice Guidelines in Oncology: Myeloid growth factors. V.I.2014,
http://www.nccn.org/professionals/physician_gls/pdf/myeloid_growth.pdfAccessed.
December 20–2014
|
